智通财经网·2025-10-31 02:06Core Viewpoint - Spring Medical (01858) has experienced a significant stock price increase of over 10%, attributed to strong financial performance in Q3 2025, with notable revenue and profit growth [1] Financial Performance - The company reported a revenue of 756 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.75% [1] - Net profit attributable to shareholders reached 192 million yuan, showing a substantial year-on-year growth of 213.21% [1] - In Q3 alone, the company achieved a revenue of 268 million yuan, marking a remarkable year-on-year increase of 109.51% [1] - The net profit for Q3 was 77.06 million yuan, indicating a turnaround from loss to profit [1] Market Expansion and Product Development - Huatai Securities attributes the rapid growth in Q3 to the company's steady progress in international market expansion and increasing export revenue [1] - The company has successfully passed CE annual system audits and supervision audits for its hip, knee, and spine product lines, indicating strong international competitiveness [1] - The knee prosthesis system has received FDA 510(k) approval, showcasing the company's technological advantages and establishing a foundation for continued growth in international sales [1]